| abstract |
Referred to a composition comprising the enantiomers of (R) -3,6,7,7a-tetrahydro-1H-pyrrolo [1,5-a] imidazole-2,5-dione ((R) -dimiracetam (1)) and (S) -3,6,7,7a-tetrahydro-1H-pyrrolo [1,5-a] imidazole-2,5-dione ((S) -dimiracetam (2)) and / or solvates or co-crystals pharmaceutically acceptable thereof; where an enantiomeric excess (ee) of (R) -dimiracetam (1) is equal to or greater than 33% and less than or equal to 54%, where the ratio of (R) -dimiracetam (1) with respect to ( S) -dimiracetam (2) is 2: 1 to 3.3: 1. Said composition exhibits a greater pharmacological potency (synergistic effect) than its corresponding individual enantiomers or racemate; being useful in the treatment and / or prevention of a disease or disorder preferably selected from peripheral sensory neuropathy, peripheral neuropathic pain, seizures, psychiatric conditions, depression or cognitive impairment |